50 results about "Simvastatin" patented technology

The invention relates to a double-active-component acute myelogenous leukemia resisting drug and application thereof. The active components of the double-active-component acute myelogenous leukemia resisting drug are composed of a first active component and a second active component, the first active component is selected from any one or a combination of at least two of simvastatin, pharmaceutically acceptable salt, isomer, solvate and metabolite of simvastatin; and the second active component is selected from any one or a combination of at least two of Selanisole, pharmaceutically acceptable salts, isomers, solvates and metabolites of the Selanisole. Research finds that combination of simvastatin and Senanisole not only can reduce the dosage of simvastatin or Senanisole and improve the medication safety, but also has the effect of improving or treating acute myelogenous leukemia more remarkably compared with single simvastatin or Senanisole, and plays a synergistic promotion effect.

The invention relates to a combined pharmaceutical composition for improving or treating follicular lymphoma, which is characterized in that the active components of the combined pharmaceutical composition consist of a first active component and a second active component, the first active component is selected from any one or a combination of at least two of simvastatin, pharmaceutically acceptable salt, isomer, solvate and metabolite of simvastatin; the second active component is selected from any one or a combination of at least two of dovirisad, pharmaceutically acceptable salt, isomer, solvate and metabolite of dovirisad. The research finds that the simvastatin and the dovirisail not only can reduce the dosage of the simvastatin or the dovirisail and improve the medication safety, but also have the effect of improving or treating follicular lymphoma more remarkably than that of single simvastatin or dovirisail, and play a synergistic promotion effect.

The invention provides a simvastatin-cholesterol compound external emulsifiable paste and application thereof in preparation of a medicine for treating keratosis perspirioides. The simvastatin-cholesterol compound external use emulsifiable paste is prepared from simvastatin, cholesterol, pharmaceutically acceptable auxiliary materials and water. According to the simvastatin-cholesterol compound external emulsifiable paste disclosed by the invention, the simvastatin and the cholesterol are combined for use, so that the treatment effect of the simvastatin-cholesterol compound external emulsifiable paste on the keratosis is remarkably improved through the synergistic interaction of the simvastatin and the cholesterol.

Disclosed are methods of treating or preventing or delaying the onset of Alzheimer's disease (AD) in a subject by targeting a new STAT1-CH25H pathway in the pathogenesis of AD, in particular by administering to the subject a pharmaceutically effective amount of a STAT1 inhibitor, a CH25H inhibitor, or a 25-OHC inhibitor, such as a 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor, such as simvastatin.

The invention discloses a core-shell structure microneedle patch loaded with tetracycline antibacterial drugs and simvastatin as well as a preparation method and application of the core-shell structure microneedle patch, and belongs to the field of biomedical materials. An antibacterial drug doxycycline is loaded on a shell structure of a substrate layer and a needle body of the microneedle patch, and a core structure contains simvastatin-loaded polydopamine nanoparticles. The microneedle patch can release antibacterial drugs in stages, and the number of bacteria at local parts of a focus can be rapidly reduced in a short time through burst release of the antibacterial drugs in the first stage, so that inflammation spreading is controlled; in the second stage, the antibacterial medicine is slowly released, so that the formation of a new plaque biofilm is inhibited for a long time, meanwhile, simvastatin is slowly released, the effect of locally promoting osteogenesis is achieved, and the synergistic effect of antibiosis and bone regeneration is achieved. The compound has a good application prospect in the treatment of chronic periodontitis, especially intractable periodontitis combined with systemic diseases, such as chronic periodontitis combined with diabetes mellitus.

The invention relates to a traditional Chinese medicine composition for treating portal vein and hepatic sinus vascular diseases. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 13-17 parts of astragalus membranaceus, 13-17 parts of angelica sinensis and 4-8 parts of leech. The invention also provides application of the traditional Chinese medicine composition in preparation of medicines for treating portal vein and hepatic sinus vascular diseases. According to the invention, an SD (Sprague Dawley) rat is fed with selenium-rich diet, meanwhile, a model is made according to a chemotherapy regimen of FOLFOX intravenously injected into the tail of the rat every week, the model is made continuously for 8 weeks, a PSVD animal model is copied, the modified Chinese angelica blood replenishing decoction is fed for intervention while the model is made, and simvastatin is taken as a positive control. Results show that the modified Chinese angelica blood replenishing decoction can significantly reduce the portal vein pressure of rats and improve related expressions of liver microangiopathy. The liver index is obviously reduced, and the spleen index is improved. Liver tissue pathological reticular staining and Japanese stellate red staining show that both the liver tissue and the Japanese stellate red staining are relieved.

The invention relates to the field of biological material science and the field of material science, in particular to a preparation method and application of asymmetric adhesion hydrogel powder for clinical treatment of pleural adhesion. The preparation method comprises the following steps: firstly, preparing hydroformylated hyaluronic acid (HAA) and 5-hydroxydopamine silk fibroin (5-HDP-SF), and preparing lipidosome loaded with simvastatin and miRNA-124 by using a film method; the synthesized HAA, epsilon-polylysine. HCl and 5-HDP-SF are mixed according to a certain mass ratio, sodium hydroxide (NaOH) is added to adjust the pH value, and then adhesive layer hydrogel is formed; dispersing the prepared lipidosome loaded with simvastatin and miRNA-124 into the adhesive layer hydrogel, and then freeze-drying to obtain adhesive layer hydrogel powder (loaded lipidosome); the synthesized HAA and four-arm sulfydryl polyethylene glycol (4-arm-PEG-SH) are mixed according to a certain mass ratio and then freeze-dried, and non-adhesive layer hydrogel powder can be formed; and dissolving the adhesive layer hydrogel powder again to obtain adhesive layer hydrogel, and smearing the non-adhesive layer hydrogel powder on the upper surface of the adhesive layer hydrogel according to a certain mass ratio to obtain the asymmetric adhesive hydrogel (loaded liposome). The hydrogel prepared by the invention is loaded with simvastatin and miRNA-124 at the same time, can be used for synergistically treating pleural adhesion, has good biocompatibility and mechanical adaptability, and has a quite wide application prospect in the field of biological medicines.

This invention relates to extracts of traditional Chinese medicine, and particularly to the application of a compound extract with lipid-regulating effects in the preparation of lipid-regulating drugs. Experimental studies of this invention have found that a compound traditional Chinese medicine lipid-regulating formula, administered for 14 weeks, can effectively reduce serum total cholesterol levels in hyperlipidemic mice. Furthermore, the lipid-lowering effects of the compound formula at 7.08 g / kg (high-dose group) and 3.54 g / kg (low-dose group) in hyperlipidemic mice are similar to those of simvastatin. Moreover, the dosage of the lipid-regulating compound formula is lower. This important compound lipid-regulating formula described in this invention can be applied to the prevention and treatment of hyperlipidemia, providing a new option for the prevention and treatment of hyperlipidemia.

This invention obtains a stable ezetimibesimvastatin pharmaceutical composition by combining β-cyclodextrin and sulfite antioxidants. This pharmaceutical composition has better stability and satisfactory dissolution effect than the reference formulation. Furthermore, the preparation method of the ezetimibesimvastatin pharmaceutical composition of this invention is simple, the process does not require the use of organic solvents, and no special treatment is required, making it very suitable for industrial production.

The invention discloses an application of simvastatin in preparation of a medicine for treating post-traumatic stress disorder. According to the invention, a post-traumatic stress disorder model is firstly constructed, and a result shows that in post-traumatic stress disorder model animals, obvious core behavior characteristics such as fear memory overconsolidation and anxiety behavior enhancement are shown. When simvastatin is used for intervention treatment, the fear memory fading ability of the model animal is obviously improved, and the anxiety behavior is obviously relieved; behavior experiment comprehensive evaluation shows that the stiffness time of animals in a simvastatin treatment group is remarkably shortened, the standing time and distance proportion of an open arm of an elevated cross maze are remarkably increased, the total movement distance of an open field experiment is remarkably increased, and simvastatin can effectively relieve fear memory disorder and anxiety behaviors of post-traumatic stress disorder model animals.

The invention belongs to the technical field of medicine analysis and detection, and particularly relates to a high performance liquid chromatography method for related substances of a flutemevitamin three-component preparation. According to the method, a specific chromatographic column, a mobile phase type, a mobile phase proportion and a gradient elution procedure are used, and only when the parameters are met at the same time, good detection separation degree, sensitivity and specificity can be ensured, so that accurate and rapid detection of related substances in the flutemevir three-component preparation is realized; the successful application of the technology is helpful for improving the quality level of a medicinal preparation, ensuring the medication safety of a patient, and making a positive contribution to the development of the field of medicine research and development.

The invention belongs to the technical field of chromatographic detection, and provides a simvastatin detection method and application thereof. According to the detection method disclosed by the invention, qualitative and quantitative detection of simvastatin in a sample can be realized by adopting a high performance liquid chromatography-tandem mass spectrometry mode. In the high performance liquid chromatography detection, the simvastatin possibly existing in the red yeast rice powder and the product thereof can be detected by combining a pentafluorophenyl propyl chromatographic column and a formic acid methanol mobile phase. The detection method provided by the invention can effectively distinguish the statins and simvastatin naturally existing in the red yeast rice powder, and can effectively avoid the false positive result of simvastatin detection; the method can also be applied to detection of various products including capsules, tablets, oral liquid and the like containing the red yeast rice powder, and various quality monitoring scenes can be considered.

The invention provides a blood fat-reducing ganoderma lucidum spore powder pharmaceutical composition as well as a preparation method and application thereof, and belongs to the technical field of medicines. Comprising a ganoderma lucidum spore powder extract and a pharmaceutical composition, and the mass ratio of the ganoderma lucidum spore powder extract to the pharmaceutical composition is 10: (1-2); the pharmaceutical composition contains a simvastatin derivative and an apatamuron derivative. The prepared blood-fat-reducing ganoderma lucidum spore powder pharmaceutical composition adopts a mixed preparation of traditional Chinese medicine components and western medicine components, has complementary advantages, can quickly reduce cholesterol content and take effect quickly on one hand, can fundamentally inhibit cholesterol synthesis and improve metabolic disorder of hyperlipidemia on the other hand, and is small in side effect, high in patient compliance, good in effect and free of toxic and side effects on the other hand. Certain anti-inflammatory, anti-thrombotic and anti-tumor effects and the like are achieved, and the application prospect is wide.

The present disclosure relates to a high-drug-loading molecular state simvastatin skin ointment and a preparation process therefor. The ointment comprises simvastatin and a basic matrix composition. The basic matrix composition comprises a basic matrix, a solubilizer, a consistency regulator, a stabilizer, and the like. According to the ointment of the present disclosure, simvastatin is stably present in the basic matrix composition in the form of molecules. Phospholipid and cholesterol, as the solubilizer and the stabilizer, are self-assembled in a non-aqueous solution to form a reverse micelle structure, thereby enhancing the stability of a drug. Meanwhile, the solubility of a weak-polarity drug is increased by means of the reverse micelle system, so that the skin retention amount can be greatly increased when the reverse micelle system is used as a percutaneous administration carrier, thereby enhancing the percutaneous absorption of the drug. The formulation of the present disclosure is easy to prepare, good in storage stability, high in drug loading, high in drug accumulation amount in skin, easy to permeate, and quick to take effect, thereby avoiding side effects caused by oral simvastatin.

This invention discloses a yeast strain with weakened acyl donor degradation, a modification method, and its application in the synthesis of simvastatin, belonging to the field of genetic engineering. It describes a synthetic pathway for heterologous expression of simvastatin using Pichia pastoris as the host, with exogenously added α-dimethylbutyryl- S methyl mercaptopropionate (DMB-) S Simvastatin biosynthesis is achieved using MMP as an acyl donor. This invention significantly reduces the Pichia pastoris's reliance on DMB- by knocking out genes 2, 19, and 18 in the Pichia pastoris genome. S Degradation efficiency of simvastatin. Recombinant strains mlow-SV(Δ2Δ19) and mlow-SV(Δ2Δ19Δ18) produced 7.94 mg / L and 10.37 mg / L simvastatin, respectively, after 72 h of shake-flask fermentation, representing increases of 201.4% and 293.6% compared to recombinant strain mlow-SV(Δku70).

The invention relates to the technical field of preparation of antitumor drugs, in particular to a drug delivery system based on mesoporous polydopamine and a preparation method and application thereof. The mesoporous polydopamine and the substrate are used for loading hydrophobic simvastatin, cholesterol oxidase and manganese acetate at the same time, and the nano composite material coated with hyaluronic acid has good drug loading capacity, realizes targeted release of drugs, and kills tumor cells and inhibits proliferation of the tumor cells through consumption of the drugs on tumor cell cholesterol.

The invention discloses a ZIF-8 entrapped simvastatin nano material as well as a preparation method and application thereof, and belongs to the technical field of biological materials. Aiming at the problem of low drug loading capacity in the existing preparation method of the ZIF-8 entrapped simvastatin nano material, the preparation method comprises the following steps: firstly, mixing SV and methylimidazole and stirring to obtain a mixed solution A; then dropwise adding a zinc nitrate solution into the mixed solution A while stirring to obtain a mixed solution B; and finally, carrying out centrifugal treatment on the mixed solution B, washing with methanol for three times until the supernatant is clear, and naturally drying to obtain the SV (at) ZIF-8. The particle size of the SV (at) ZIF-8 prepared by the preparation method can be controlled below 100nm, and the SV (at) ZIF-8 has good stability, drug loading capacity and slow-release effect, can realize stable and continuous slow release of SV, plays a positive role of Zn ions in promoting osteogenesis, and has a significant effect on promoting early clinical application of SV. The bone defect repairing curative effect is improved, the treatment time is shortened, the treatment risk and the treatment cost are reduced, and the important practical significance is achieved.

The invention relates to the technical field of medicine detection, in particular to a method for detecting ezetimibe simvastatin tablets with a distinguishing force dissolution curve, which comprises the following steps: respectively using a buffer solution containing 0.2-0.3 wt% of lauryl sodium sulfate and having a pH value of 1-7 and a buffer solution containing 0.05-0.10 wt% of lauryl sodium sulfate and having a pH value of 4.5-7 as dissolution media, and performing dissolution by adopting a slurry method, so as to obtain the ezetimibe simvastatin tablets with the distinguishing force dissolution curve. And carrying out liquid phase analysis after sampling at regular time. The ezetimibe and simvastatin tablet is subjected to dissolution detection through the first dissolution medium and the second dissolution medium, so that the dissolution curve is established, the changes of the prescription and the process of the ezetimibe and simvastatin tablet are effectively distinguished, the ezetimibe and simvastatin tablet is rapidly detected, the dissolution and release rates of the ezetimibe and simvastatin tablet in a living body are predicted, and the detection accuracy of the ezetimibe and simvastatin tablet is improved. Therefore, the number of times of bioequivalence of the human body is reduced, and finally the purposes of reducing the input cost and improving the research and development efficiency are achieved.

The present invention belongs to the technical field of pharmaceutical preparation application, and provides an enzyme-responsive silica nanoformulation, a preparation method and an application. The present invention intends to use simvastatin as a model drug, and then polyethyleneimine and hyaluronic acid are modified layer by layer on the outer surface of mesoporous silica nanoparticles to form an enzyme-responsive silica nanoformulation. The preparation steps are as follows: 1) synthesizing mesoporous silica nanoparticles under alkaline conditions; 2) loading simvastatin into the pores of the nanoparticles; 3) respectively coating polyethyleneimine and hyaluronic acid layer by layer on the outer surface of the mesoporous silica nanoparticles, and finally obtaining an enzyme-responsive silica nanoformulation. An enzyme-responsive silica nanoformulation of the present invention has the characteristics of uniform particle size, good dispersibility, high drug loading and low toxicity, and can trigger the enzyme response characteristics to release drugs in a high-concentration enzyme environment at the lesion site to improve its anti-atherosclerotic effect.

The application discloses simvastatin-beta-cyclodextrin nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines, wherein the simvastatin-beta-cyclodextrin conjugate has active oxygen responsiveness, comprises an ester bond connection structure formed by a beta-cyclodextrin hydroxyl group, a thio-ketone connection unit and a simvastatin hydroxyl group, and the thio-ketone connection unit is a thio-ketone dicarboxylic acid residue formed by condensation of 3-mercaptopropionic acid and acetone; the simvastatin-beta-cyclodextrin conjugate can self-assemble to form simvastatin-beta-cyclodextrin nanoparticles. The active oxygen responsive simvastatin-beta-cyclodextrin conjugate provided by the application can dissociate in an oxidative stress related environment, realizes double-path cholesterol homeostasis regulation functions of inhibiting cholesterol synthesis and promoting cholesterol efflux, reduces the degree of macrophage foam, and further reduces the lipid load of an atherosclerotic plaque.

The present invention relates to a combination of an HDAC inhibitor and statins for use in the treatment of pancreatic cancer. Preferably the invention relates to a combination of valproic acid (VPA) or any of its salts and simvastatin (SIM). The combination of the invention synergistically improves the anti-proliferative and pro-apoptotic effect of conventional chemotherapy, as gemcitabine / taxol.

The invention relates to the technical field of traditional Chinese medicine, in particular to a composition for rapidly reversing and fading atheromatous plaques, a preparation and a preparation method, and the composition provided by the invention comprises hevea brasiliensis seed oil, pseudo-ginseng, ginseng and policosanol. The composition disclosed by the invention is reasonable in compatibility, has the effects of regulating glycolipid metabolism, stabilizing and reducing atherosclerotic plaque and protecting vascular elasticity, and has the effects of reducing whole blood viscosity and plasma viscosity and obviously reducing the plaque and reducing the plaque volume compared with western medicine simvastatin. Therefore, the medicine disclosed by the invention combines tonifying and eliminating, is safer, more effective, mild and lasting, has a multi-target and multi-effect action mechanism, can remarkably reverse and eliminate atherosclerotic plaques, provides theoretical support for the research of the traditional Chinese medicine channel tropism theory, and provides a safer treatment product for atherosclerotic patients.

The present invention relates to a modified metal, a preparation method thereof and an application. The modified metal comprises a metal and a film layer located on the surface of the metal. Among them, the metal comprises one or more of titanium, tantalum, and magnesium, and the film layer comprises a statin compound, and the statin compound comprises one or more of simvastatin, pravastatin, atorvastatin, and rosuvastatin. The modified metal of the present invention has good antibacterial properties and can effectively avoid the infection of the orthopedic implants produced.

The invention provides a simvastatin microcrystal stock solution and a preparation method thereof as well as a simvastatin pharmaceutical composition and application thereof, and belongs to the technical field of pharmaceutical preparations. The simvastatin microcrystal stock solution comprises simvastatin microcrystals, a stabilizer and water. The preparation method of the simvastatin microcrystal stock solution comprises the following steps: dissolving the stabilizer in water, adding the simvastatin raw material medicine, uniformly stirring, and then carrying out wet grinding to obtain the simvastatin microcrystal stock solution. The simvastatin pharmaceutical composition comprises a simvastatin microcrystal stock solution and is obtained by diluting the simvastatin microcrystal stock solution with a solution, the simvastatin pharmaceutical composition has the characteristics of high stability and good redissolvability, the slow release effect is achieved after injection, and the effective blood concentration can be achieved with a low dosage.

The application belongs to the technical field of simvastatin sodium tablet production, in particular to a raw material feeding device for simvastatin sodium tablet production and processing, which comprises a shell, a mixing barrel, a driving assembly, a mounting assembly and a mixing assembly. The mixing barrel is rotatably connected to the inner bottom of the shell through a guide mechanism, and the driving assembly is fixedly connected to the bottom of the shell. The driving assembly comprises a driving motor, a main shaft and a mounting bracket. The mounting bracket is fixedly connected to the bottom of the shell, the driving motor is fixedly connected to the inner wall of the mounting bracket, the output end of the driving motor is fixedly connected with a worm, and the main shaft is fixedly sleeved with a worm wheel engaged with the worm. One end of the main shaft penetrates through the bottom of the shell and the mixing barrel and extends upward, and the inner top of the shell is fixedly connected with a support mechanism corresponding to the main shaft. The automatic mixing mechanism can quickly and fully mix the simvastatin sodium tablet processing raw materials, thereby effectively improving the use effect of the feeding device.

The invention relates to application of an ATG5-dependent STING activator to treatment of melanoma, simvastatin or pharmaceutically acceptable salt thereof is used for preparing a medicine for activating a cGAS-STING pathway and remodeling a melanoma immune microenvironment, dendritic cell maturation and antigen cross presentation are promoted, CD8 T cells are activated, the infiltration level of the CD8 T cells and the secretion ability of IFN-gamma and TNF-alpha are improved, and the melanoma immune microenvironment is improved. Meanwhile, the expression of depletion marker proteins PD-1, TIM3 and CD39 is down-regulated, so that the conversion from immune cold tumors to thermal tumors is realized. By activating a key cGAS-STING pathway in the dendritic cells, death of immunogenic cells can be efficiently induced, and maturation and antigen presentation of the dendritic cells are promoted, so that cold tumors are converted into hot tumors, the problem of drug resistance in immunotherapy is solved, and anti-tumor immune response is improved.

The application discloses a preparation method of glucose oxidase / simvastatin magnetic nanomotor, and steps are as follows: FeCl3.6H2O is added into deionized water and stirred, sodium citrate, urea and PAM are added, and after stirring, reaction is carried out in a Teflon autoclave to obtain Fe3O4 nano solution; PAA and ammonia water are added and stirred, and then isopropyl alcohol is added dropwise to obtain Fe3O4-PAA nano solution; tetraethyl orthosilicate is added and stirred, and then washing is carried out to obtain Fe3O4-PAA / mSiO2 nano solution; simvastatin is mixed with the nano solution to obtain Sim-loaded Fe3O4-PAA / mSiO2 nanoparticles; EDC and NHS solution are added and stirred, and then glucose oxidase is added, and finally glucose oxidase-simvastatin magnetic nanomotor is obtained; the method utilizes the driving of the magnetic nanomotor in the magnetic field and the catalytic reaction of GOx, enhances the targeting and permeability of the drug in the tumor, and the loaded simvastatin can affect the lipid metabolism of tumor cells and inhibit glucose uptake, and compared with the use of GOx alone, the anti-tumor activity is significantly improved.

The invention discloses tea exosome-like vesicles entrapped with simvastatin and a preparation method of the tea exosome-like vesicles entrapped with simvastatin. The tea exosome-like vesicles entrapped with simvastatin comprise simvastatin and tea exosome-like vesicles entrapped with simvastatin, the tea exosome-like vesicles are prepared from fresh tea leaves and a PEG6000 solution; targeted delivery of statins is realized by entrapping simvastatin with tea exosome-like vesicles, so that toxic and side effects of the statins are reduced, and it is surprisingly found that simvastatin entrapped with tea exosome-like vesicles has a synergistic effect on improving the lipid-lowering effect.

The present disclosure relates to a high-drug-loading molecular state simvastatin skin ointment and a preparation process therefor. The ointment comprises simvastatin and a basic matrix composition. The basic matrix composition comprises a basic matrix, a solubilizer, a consistency regulator, a stabilizer, and the like. According to the ointment of the present disclosure, simvastatin is stably present in the basic matrix composition in the form of molecules. Phospholipid and cholesterol, as the solubilizer and the stabilizer, are self-assembled in a non-aqueous solution to form a reverse micelle structure, thereby enhancing the stability of a drug. Meanwhile, the solubility of a weak-polarity drug is increased by means of the reverse micelle system, so that the skin retention amount can be greatly increased when the reverse micelle system is used as a percutaneous administration carrier, thereby enhancing the percutaneous absorption of the drug. The formulation of the present disclosure is easy to prepare, good in storage stability, high in drug loading, high in drug accumulation amount in skin, easy to permeate, and quick to take effect, thereby avoiding side effects caused by oral simvastatin.